Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. - Wikidata - wikimedia - TriplyDB

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

http://www.wikidata.org/entity/Q33401982

about

Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies Oral drugs in the treatment of metastatic colorectal cancer.Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape?Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer.The antibodies against 5-bromo-2'-deoxyuridine specifically recognize trifluridine incorporated into DNA.Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.Novel developments in the use of antimetabolites.DNA synthesis inhibitors for the treatment of gastrointestinal cancer.Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.TAS-102, a novel antitumor agent: a review of the mechanism of action.TAS-102 for the treatment of metastatic colorectal cancer.TAS-102: a novel antimetabolite for the 21st century.A novel antimetabolite: TAS-102 for metastatic colorectal cancer.Nucleoside analogs: ready to enter the era of precision medicine?Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse.Radiosensitization by thymidine phosphorylase inhibitor in thymidine phosphorylase negative and overexpressing bladder cancer cell lines.The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report.Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy.Trifluridine/Tipiracil: Old Drug, New Tricks.Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil.Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine.Combined efficacy and mechanism of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell lines.A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil.MBD4 frameshift mutation caused by DNA mismatch repair deficiency enhances cytotoxicity by trifluridine, an active antitumor agent of TAS-102, in colorectal cancer cells.Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression.

P2860

Q26777679-AE8AA628-17B1-4F63-8667-F83E0836BFB1 Q30251387-EA9E9FA6-1FD3-4B10-8D33-799615A506BA Q33167150-421AD6FB-D266-4250-9E71-90C908EAD45C Q33434890-FA18C087-D697-4B37-8CE0-86BFF4FC5DEB Q36067756-3093F1CC-9775-4E4C-81BB-4A5C6700C3C1 Q36076767-93E0E697-0160-45DE-B793-11F345FCCD8F Q36181265-19558654-8033-4D73-898B-4DFBEDF5423B Q36619557-2B0C53F5-2DA6-4F06-B8D7-719363F985DD Q36621566-D76038F4-68DA-4148-8FF6-91C92A59A5D2 Q36860056-266F527F-3F9F-49D6-95FF-4B14B3760C4C Q37146675-9FE57955-57D3-4C3F-A775-A460F3C6C343 Q37588632-8FA90F32-5C73-4037-81CA-B89DED5EE608 Q37703201-3BC29A41-8BEC-445D-BE0B-DA5393273B38 Q38204673-19BFC679-301D-4469-BED8-4CC7B4C55BDF Q38221152-2A9F3E3D-8FCB-4C60-B63E-5F18E3D3BFB2 Q38254307-972890AA-79FA-4D98-B23E-A8DEC7365258 Q38427767-08708374-DA72-4FFE-84AE-E7EEFFED0F73 Q38597310-EAEA42C8-3D0F-4AC3-9549-3937872F03C5 Q38618169-A3531255-D1C4-4B39-8E13-96F833CC3216 Q38652269-F0633525-E061-4594-B89E-76BE743B022B Q38671965-63CDD2B3-6517-4408-B7B5-9ED4D64E661D Q38842938-1BE3E89E-FEE6-476B-84A2-3EC28AE0BFCD Q38862939-CDFBB795-DB95-415F-94B8-8CFCDC4A7A3D Q38983467-131CC0A5-5BD0-4036-A375-18355D27031F Q39003096-BD911850-9B2F-4EC3-9081-1E254EBC7EAC Q40081348-B3718133-9E5B-452A-96D9-6A97ED660426 Q42361962-744DFA0E-D97D-4589-B5B2-BF3E623C7ABC Q46265532-61BD8F17-0FD5-4621-8C70-6AF232A6E252 Q47141058-CAC046C8-314B-4924-8617-5A25E1534E92 Q48153064-1D0439C2-43DF-4FC3-B0F4-BAA167D7DC68 Q50128950-28DA2920-E921-4DAF-8425-4EB79ECC4D7C Q50960428-C673E784-CA7C-4FFC-A34F-74597B32811B Q52653022-C6D628B5-B1F5-4E5B-95BC-F613AEDB490A Q55006325-136096E4-70C1-4EEC-8030-F5FCCFB7962D

P2860

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

http://www.wikidata.org/entity/Q33401982

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

@ast

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

@en

type

label

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

@ast

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

@en

prefLabel

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

@ast

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

@en

P1433

Q33401982-3139E1EB-B65A-471B-A5E3-B69690124E5A

P1476

Q33401982-93D87C51-2F80-45DB-9FB4-857CE9E38A37

P2093

Q33401982-0DB83879-9BBE-4E34-8BDD-E65BC1F7D991

Q33401982-0DDD0F49-2610-42DB-8763-F2AB77B55E02

Q33401982-16EF4CD2-FB77-4C9B-9F21-F7CB0A15D056

Q33401982-1BBE891A-EBD7-4F95-B982-AA6B49FBD110

Q33401982-22474FE1-37B7-4C78-9D60-EC267AE7F865

Q33401982-4E903DCC-D0CC-492D-86A9-5C891831E5E6

Q33401982-631D04CD-CBBB-4ACF-96DB-6057D2AFCCCE

Q33401982-70BA2C85-E1D9-4D64-B761-85DFB73DC543

Q33401982-FEC8BB7B-2A6A-4E05-B098-B1769C76BF63

P2860

Q33401982-0A04ACA5-F737-474A-A60A-C043DA03CCA8

Q33401982-12F4AD32-D460-4C43-86A4-6BBDA292B5EB

Q33401982-1BAD7DB8-CF46-4813-BF41-47F720F58042

Q33401982-3688A444-4310-4C45-AB33-E7B6D394CF8C

Q33401982-40424E59-3F16-4DFD-A60F-AA17FC1B3555

Q33401982-7BD8B0E6-A4D4-43AA-92B3-FE3CC2EBCCDB

Q33401982-98857D48-F050-477D-B381-48C8C9BF2EAB

Q33401982-A5BDE3DC-136F-42ED-AEC8-A3F9B634C9E7

Q33401982-B1FE66F1-B062-4908-AC52-1353EC53268A

Q33401982-CA8ED348-B177-4D3D-801E-6AD914656CC9

P2888

Q33401982-27EB60C3-0140-4943-BCE0-7617D8D0241E

P304

Q33401982-8AE8273D-D058-41DE-A502-30AA2D87F257

P31

Q33401982-DFA14632-8FBB-42B8-A5E6-D96A758F80D3

P356

Q33401982-6706D5B2-F239-4894-B6E3-30BCFA5A4024

P407

Q33401982-5C364D9C-33AD-4A26-A2E5-C4FE3189542F

P433

Q33401982-4880E381-297B-43F4-B11B-D6CFA3086BCB

P478

Q33401982-992D5AF9-D4F0-4232-B96F-460E17990605

P577

Q33401982-648456E6-D986-477F-8ED3-1D64D173FA31

P5875

Q33401982-8E0AE38C-71B5-410A-9C94-A6A5994F142A

P6179

Q33401982-220D8825-7F25-4A23-BAC7-7205B46F888C

P698

Q33401982-C2A24A92-8219-4516-B91E-D2E5C84AFD02

P921

Q33401982-79911191-02EE-41DA-A59E-919585DA1351

P932

Q33401982-F02C132E-1A3E-4687-90EF-1C61C10473C1

P356

P1433

British Journal of Cancer

P1476

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.

@en

P2093

A Fukutomi

http://www.w3.org/2001/XMLSchema#string

A Ohtsu

http://www.w3.org/2001/XMLSchema#string

N Boku

http://www.w3.org/2001/XMLSchema#string

S Hironaka

http://www.w3.org/2001/XMLSchema#string

T Doi

http://www.w3.org/2001/XMLSchema#string

T Sasaki

http://www.w3.org/2001/XMLSchema#string

T Yoshino

http://www.w3.org/2001/XMLSchema#string

W Koizumi

http://www.w3.org/2001/XMLSchema#string

Y Onozawa

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520).

A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.

Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.

Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.

Incorporation of 2'-deoxy-5-(trifluoromethyl)uridine and 5-cyano-2'-deoxyuridine into DNA.

An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.

Mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes.

P2888

P304

429-434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2012.274

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228070754

http://www.w3.org/2001/XMLSchema#string

P6179

1046658212

http://www.w3.org/2001/XMLSchema#string

P698

22735906

http://www.w3.org/2001/XMLSchema#string

P921

P932

3405214

http://www.w3.org/2001/XMLSchema#string